Read by QxMD icon Read

Progressive multiple sclerosis treatment

Hussein Algahtani, Bader Shirah, Hind Abobaker, Nebras Alghanaim, Fatemah Kamel
BACKGROUND: Natalizumab is the first targeted humanized monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab appears to be more effective than current first-line disease-modifying therapies. In our study, we aimed to evaluate the outcome of Saudi patients with active RRMS treated with natalizumab and compare the results with other outcomes in the Gulf and international trials. METHODS: We conducted a retrospective single-center observational study involving 32 patients with RRMS at King Abdulaziz Medical City in Jeddah, Saudi Arabia...
September 18, 2018: Clinical Neuropharmacology
Bo-Zong Shao, Qi Cao, Chong Liu
Central nervous system (CNS) is one of the largest killers of people's health all over the world. The overactivation of the immune and inflammatory responses is considered as an important factor, contributing to the pathogenesis and progression of CNS disorders. Among all kinds of immune and inflammatory reaction, the inflammasome, a complex of proteins, has been drawn increasingly attention to by researchers. The initiation and activation of the inflammasome is involved in the onset of various kinds of diseases...
2018: Frontiers in Molecular Neuroscience
Francois Grand'Maison, Michael Yeung, Sarah A Morrow, Liesly Lee, Francois Emond, Brian J Ward, Pierre Laneuville, Robyn Schecter
Multiple sclerosis (MS) is characterized by chronic inflammation in conjunction with neurodegeneration within the central nervous system. Most individuals with MS begin with a relapsing remitting course that later transitions to secondary progressive MS. Currently available disease-modifying therapies (DMTs) for relapsing MS have been demonstrated to reduce disease activity, however most patients require a change in therapy over the course of their disease. Treatment goals include the prevention of relapses and disability accumulation and to achieve this objective requires careful planning...
November 2018: Neural Regeneration Research
Suyog Pol, Michele Sveinsson, Michelle Sudyn, Natan Babek, Danielle Siebert, Nicola Bertolino, Claire M Modica, Marilena Preda, Ferdinand Schweser, Robert Zivadinov
BACKGROUND AND PURPOSE: Teriflunomide reduces disability progression and brain atrophy in multiple sclerosis patients. The exact mechanism of action by which teriflunomide exerts these effects is currently unknown. We assessed the effect of teriflunomide on brain glial cells in the Theiler's murine encephalomyelitis virus (TMEV) by using a histological approach in combination with neuroimaging. METHODS: Forty-eight SJL female mice received an intracerebral injection of TMEV at 6-8 weeks of age and were then treated with teriflunomide (n = 24) or placebo (n = 24) for 9 months...
September 19, 2018: Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging
Xueli Yu, Gang Cheng, Lei Zhang, Yu Zhang, Qing Wang, Mengxue Zhao, Limin Zeng, Youhong Hu, Linyin Feng
Oligodendrocytes are a type of glial cells that ensheath multiple neuronal axons and form myelin. Under pathological conditions, such as multiple sclerosis (MS), inflammatory damage to myelin and oligodendrocytes leads to demyelination. Although the demyelinated regions can partially resolve functional deficits through remyelination, however, as the disease progresses, remyelination typically becomes incomplete and ultimately fails. One possible explanation for this failure is the activation of the Notch pathway in MS lesions, which impedes oligodendrocyte precursor cells (OPCs) at maturation...
September 19, 2018: Scientific Reports
Fernando Laso-García, Jaime Ramos-Cejudo, Francisco Javier Carrillo-Salinas, Laura Otero-Ortega, Ana Feliú, MariCarmen Gómez-de Frutos, Miriam Mecha, Exuperio Díez-Tejedor, Carmen Guaza, María Gutiérrez-Fernández
Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication and as possible therapeutic agents in inflammation-mediated demyelinating diseases, including multiple sclerosis (MS). In the present study, we investigated whether intravenously administered EVs derived from mesenchymal stem cells (MSCs) from human adipose tissue might mediate recovery in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease, a progressive model of MS. SJL/J mice were subjected to EV treatment once the disease was established...
2018: PloS One
Q An, C-H Fan, S-M Xu
Multiple sclerosis (MS) is an inflammatory idiopathic autoimmune disease causing demyelination of central nervous system (CNS). The incidence of pediatric MS is relatively rare, affecting 0.2 to 0.64/100,000 subjects; cases with MS onset before age 10-12 years, account for less than 1% of all MS cases, while 2.7 to 10.5% of all MS cases worldwide are seen in children <18 years of age, with a strong female preponderance. The disease course of MS varies from a benign type with relatively low level of disability after a long duration (15 years) of the disease, to a malignant type of MS with severe disability or even death within few months following onset...
September 2018: European Review for Medical and Pharmacological Sciences
Wendy Oost, Nynke Talma, Jan F Meilof, Jon D Laman
Multiple sclerosis (MS) is a chronic and often progressive, demyelinating disease of the central nervous system (CNS) white and gray matter and the single most common cause of disability in young adults. Age is one of the factors most strongly influencing the course of progression in MS. One of the hallmarks of aging is cellular senescence. The elimination of senescent cells with senolytics has very recently been shown to delay age-related dysfunction in animal models for other neurological diseases. In this review, the possible link between cellular senescence and the progression of MS is discussed, and the potential use of senolytics as a treatment for progressive MS is explored...
September 18, 2018: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
Paola Perini, Francesca Rinaldi, Marco Puthenparampil, Michela Marcon, Francesco Perini, Paolo Gallo
BACKGROUND: Dimethyl fumarate (DMF) is approved as first line therapy for relapsing-remitting multiple sclerosis (RRMS). In some (3%) patients, DMF induces a marked lymphopenia. Herpes simplex encephalitis (HSE) may occur in lymphopenic subjects under treatment with immune-suppressive drugs. CASE PRESENTATION: We report a case of a 39-year-old female patient with RRMS that developed HSE temporally associated with a marked and sudden drop in lymphocyte count, from 1200/µl to 600/µl, in the peripheral blood...
September 11, 2018: Multiple Sclerosis and related Disorders
María C Ysrraelit, Jorge Correale
Multiple sclerosis (MS) is a chronic inflammatory disease of the Central Nervous System (CNS) affecting young people and leading to demyelination and neurodegeneration. The disease is clearly more common in women in whom incidence has been rising. Gender differences include: earlier disease onset and more frequent relapses in women; and faster progression and worse outcomes in men. Hormone-related physiological conditions in women such as puberty, pregnancy, puerperium and menopause also exert significant influence both on disease prevalence as well as on outcomes...
September 17, 2018: Immunology
Barcutean Laura Iulia, Romaniuc Andreea, Maier Smaranda, Bajko Zoltan, Motataianu Anca, Hutanu Adina, Simu Iunius, Andone Sebastian, Balasa Rodica
Introduction We evaluated the peripheral immune panel of multiple sclerosis (MS) patients treated for more than 10 years with interferon-beta1b (IFNβ-1b) and aimed to identify possible biomarkers of treatment response. Material and Methods Serum samples from 70 MS patients treated with IFNβ-1b more than a decade were analysed for 15 cytokines, that were correlated with the disability score, annual relapse ratio (ARR): the total number of relapses-ARR_0, relapses on treatment-ARR_1 and demographic data. Two groups were defined based on the levels of disability, calculated using the Expanded Disability Status Scale (EDSS): G1 - recurrent-remissive and G2 - secondary-progressive...
September 16, 2018: CNS & Neurological Disorders Drug Targets
Hung Nguyen, Sydney Zarriello, Alexandreya Coats, Cannon Nelson, Chase Kingsbury, Anna Gorsky, Mira Rajani, Elliot G Neal, Cesar V Borlongan
Age-related neurological disorders continue to pose a significant societal and economic burden. Aging is a complex phenomenon that affects many aspects of the human body. Specifically, aging can have detrimental effects on the progression of brain diseases and endogenous stem cells. Stem cell therapies possess promising potential to mitigate the neurological symptoms of such diseases. However, aging presents a major obstacle for maximum efficacy of these treatments. In this review, we discuss current preclinical and clinical literature to highlight the interactions between aging, stem cell therapy, and the progression of major neurological disease states such as Parkinson's disease, Huntington's disease, stroke, traumatic brain injury, amyotrophic lateral sclerosis, multiple sclerosis, and multiple system atrophy...
September 13, 2018: Neurobiology of Disease
Anthony Traboulsee, David K B Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Aaron Miller
BACKGROUND: In the PRISMS study, interferon beta-1a subcutaneously (IFN β-1a SC) reduced clinical and radiological disease burden at 2 years in patients with relapsing-remitting multiple sclerosis. The study aimed to characterize efficacy of IFN β-1a SC 44 μg and 22 μg three times weekly (tiw) at Year 1. METHODS: Exploratory endpoints included annualized relapse rate (ARR), 3-month confirmed disability progression (1-point Expanded Disability Status Scale increase if baseline was < 6...
September 14, 2018: BMC Neurology
Alaa Nabil Turkistani, Foziah Jabbar Alshamrani, Ghadah Faisal Shareefi, Abdulla Alsulaiman
Introduction: Tumefactive multiple sclerosis is a demyelinating disorder that appears tumor-like on MRI. To most physicians, diagnosing tumefactive MS by applying clinical, radiological, or laboratory examination like Cerebrospinal fluid (CSF) analysis, can be challenging and ultimately biopsy is necessary to confirm the diagnosis. Case presentation: This paper reports a case of a 37-year-old woman who presented with progressive headache and a strong family history of cancer and was misdiagnosed as having a CNS glioma...
August 2018: Electronic Physician
Ilya Kister, Tamar E Bacon, Gary R Cutter
Background: Short-term disease progression is well documented in clinical trials, but there are limited published data on disease course in real-life practice. Methods: Patient-derived Multiple Sclerosis Severity Score (PMSSS), a disease severity rank score, was computed at each visit for consecutive MS patients attending two large, ethnically diverse MS centers in New York metropolitan area. Disability was assessed via Patient-Determined Disease Steps (PDDS). Clinicians recorded disease subtype and relapse status at each visit, but did not rate disability...
2018: Therapeutic Advances in Neurological Disorders
Laisheng Cai, Jingwei Huang
Purpose: There is a need for biomarkers in multiple sclerosis (MS) to make an early diagnosis and monitor its progression. This study was designed to evaluate the value of neurofilament light (NFL) chain levels as cerebrospinal fluid (CSF) or blood biomarker in patients with MS by using a quantitative meta-analysis. Methods: The PubMed, Embase, and Web of Science databases were systematically searched for relevant studies. Articles in English that evaluated the utility of NFL in CSF and blood in the diagnosis of MS were included...
2018: Neuropsychiatric Disease and Treatment
S N Jonas, I Izbudak, A A Frazier, D M Harrison
BACKGROUND AND PURPOSE: Preliminary research has demonstrated that postgadolinium 3D-FLAIR MR imaging at 7T may be a valuable tool for detecting abnormal meningeal enhancement and inflammation in MS; however, researchers have not systematically investigated its longitudinal persistence. We hypothesized that persistence of meningeal enhancement in MS varies on the basis of pattern of enhancement as well as demographic and clinical factors such as treatment status, disease phenotype, and disability score...
September 13, 2018: AJNR. American Journal of Neuroradiology
David Baker, Gareth Pryce, Sandra Amor, Gavin Giovannoni, Klaus Schmierer
Although many suspected autoimmune diseases are thought to be T cell-mediated, the response to therapy indicates that depletion of B cells consistently inhibits disease activity. In multiple sclerosis, it appears that disease suppression is associated with the long-term reduction of memory B cells, which serves as a biomarker for disease activity in many other CD20+ B cell depletion-sensitive, autoimmune diseases. Following B cell depletion, the rapid repopulation by transitional (immature) and naïve (mature) B cells from the bone marrow masks the marked depletion and slow repopulation of lymphoid tissue-derived, memory B cells...
September 12, 2018: Brain: a Journal of Neurology
Emanuele D'Amico, Aurora Zanghì, Graziella Callari, Giovanna Borriello, Antonio Gallo, Giusi Graziano, Paola Valentino, Maria Buccafusca, Salvatore Cottone, Giuseppe Salemi, Paolo Ragonese, Roberto Bruno Bossio, Renato Docimo, Luigi Maria Edoardo Grimaldi, Carlo Pozzilli, Gioacchino Tedeschi, Mario Zappia, Francesco Patti
Background: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. Methods: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions)...
2018: Therapeutic Advances in Neurological Disorders
Sahar Rostami, Mohammad-Sajad Emami-Aleagha, Maryam Ghasemi-Kasman, Abdolamir Allameh
Multiple sclerosis (MS) is an inflammatory demyelinating disease, which is considered as a common autoimmune disorder in young adults. A growing number of evidences indicated that the impairment in non-neural tissues plays a significant role in pathology of MS disease. There are bidirectional relationship, metabolic activities and functional similarity between central nervous system (CNS) and kidneys which suggest that kidney tissue may exert remarkable effects on some aspects of MS disorder and CNS impairment in these patients compels the kidney to respond to central inflammation...
2018: Caspian Journal of Internal Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"